WO2006078941A3 - Nouveaux composes d'activation de la sirtuine et procedes d'utilisation associes - Google Patents

Nouveaux composes d'activation de la sirtuine et procedes d'utilisation associes Download PDF

Info

Publication number
WO2006078941A3
WO2006078941A3 PCT/US2006/002092 US2006002092W WO2006078941A3 WO 2006078941 A3 WO2006078941 A3 WO 2006078941A3 US 2006002092 W US2006002092 W US 2006002092W WO 2006078941 A3 WO2006078941 A3 WO 2006078941A3
Authority
WO
WIPO (PCT)
Prior art keywords
activating compounds
methods
sirtuin
diseases
sirtuin activating
Prior art date
Application number
PCT/US2006/002092
Other languages
English (en)
Other versions
WO2006078941A2 (fr
Inventor
Michael Milburn
Jens W Eckstein
Original Assignee
Sirtris Pharmaceuticals Inc
Michael Milburn
Jens W Eckstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc, Michael Milburn, Jens W Eckstein filed Critical Sirtris Pharmaceuticals Inc
Publication of WO2006078941A2 publication Critical patent/WO2006078941A2/fr
Publication of WO2006078941A3 publication Critical patent/WO2006078941A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des nouveaux composés d'activation de la sirtuine et des procédés d'utilisation de ceux-ci. Lesdits composés d'activation de la sirtuine peuvent être utilisés pour augmenter la durée de vie d'une cellule, et pour traiter et/ou prévenir des maladies et des troubles divers, de type : maladies ou troubles associés au vieillissement ou au stress, diabète, obésité, maladies neurodégéneratives, maladies cardiovasculaires, troubles de la coagulation sanguine, inflammation, cancer, et/ou bouffées vasomotrices. L'invention concerne également des compositions comprenant un composé d'activation de la sirtuine en combinaison avec un autre agent thérapeutique.
PCT/US2006/002092 2005-01-20 2006-01-20 Nouveaux composes d'activation de la sirtuine et procedes d'utilisation associes WO2006078941A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64591605P 2005-01-20 2005-01-20
US60/645,916 2005-01-20

Publications (2)

Publication Number Publication Date
WO2006078941A2 WO2006078941A2 (fr) 2006-07-27
WO2006078941A3 true WO2006078941A3 (fr) 2007-02-22

Family

ID=36603673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002092 WO2006078941A2 (fr) 2005-01-20 2006-01-20 Nouveaux composes d'activation de la sirtuine et procedes d'utilisation associes

Country Status (1)

Country Link
WO (1) WO2006078941A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9162083B2 (en) 2007-07-31 2015-10-20 Elc Management Llc Linoleic and Linolenic acid esters of resveratrol and cosmetic compositions
US9220669B2 (en) 2007-09-08 2015-12-29 Elc Management Llc Resveratrol ferulate compounds, compositions containing the compounds, and methods of using the same

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
AU2004312072B2 (en) 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
CA2579784C (fr) 2004-09-14 2013-02-26 Ajinomoto Omnichem S.A. Compositions topiques contenant des polyphenols phosphoryles
RU2374234C2 (ru) 2004-09-24 2009-11-27 Астразенека Аб Бензимидазольные производные, содержащие их композиции, их получение и применение
WO2006138418A2 (fr) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
EP2142669A4 (fr) * 2007-04-12 2012-01-04 Harvard College Procédés et compositions à base de sirtuine pour traiter les affections liées à la b-caténine
US8344024B2 (en) 2007-07-31 2013-01-01 Elc Management Llc Anhydrous cosmetic compositions containing resveratrol derivatives
US9295621B2 (en) 2007-07-31 2016-03-29 Elc Management Llc Emulsion cosmetic compositions containing resveratrol derivatives and silicone surfactant
US20090035236A1 (en) 2007-07-31 2009-02-05 Maes Daniel H Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent
US20120183524A1 (en) * 2007-12-21 2012-07-19 University Of Rochester Molecular targets for treatment of inflammation
JP2012511048A (ja) 2008-12-08 2012-05-17 ノースウェスタン ユニバーシティ Ｈｓｆ−１の改変方法
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US9650637B2 (en) 2012-01-24 2017-05-16 Bar-Ilan University Treatment of disease by modulation of SIRT6
WO2013111081A1 (fr) 2012-01-24 2013-08-01 Bar-Ilan University Traitement d'une maladie par modulation de sirt6
MA38837B1 (fr) 2013-07-18 2018-10-31 Novartis Ag Inhibiteurs de l'autotaxine contenant un noyau à cycle benzyle-amide cyclique hétéroaromatique
ES2968371T3 (es) 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
SG11202110406SA (en) 2019-04-11 2021-10-28 Angion Biomedica Corp Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
CN114957171B (zh) * 2022-06-21 2024-07-30 广东工业大学 一种新颖五元杂环取代的苯乙烯衍生物及其制备方法和应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356221A (en) * 1971-08-04 1974-06-12 Pfizer 1- 3-hydroxystyryl- pyridinium salts and their derivatives as whipworm control agents
EP0334119A1 (fr) * 1988-03-21 1989-09-27 Boehringer Ingelheim Pharmaceuticals Inc. Composés pour l'inhibition de la biosynthèse de métabolites de l'acide arachidonique dérivés de la lipoxygénase
EP0499415A1 (fr) * 1991-02-11 1992-08-19 Zeneca Limited Dérivés de pyridine et quinoléine, procédés pour leur fabrication et leur utilisation comme antagonistes de l'angiotensine II
US5399575A (en) * 1990-12-01 1995-03-21 Boehringer Mannheim Gmbh Pyridine compounds which have useful pharmaceutical activity
EP0754682A1 (fr) * 1994-04-06 1997-01-22 Nippon Shinyaku Company, Limited Derive d'aminostilbazole et medicament
PL172112B1 (pl) * 1993-08-09 1997-08-29 Univ Adama Mickiewicza Bromki (E)-N-dodecylo-/lub bromodecylo-/2-/3- lub 4-/hydroksy-a-stilbazoliowe i sposób otrzymywania nowych bromków (E)-N-dodecylo-/lub bromodecylo-/2-/3- lub 4-/hydroksy-a-stilbazoliowych
JP2001261649A (ja) * 2000-03-15 2001-09-26 Sankyo Co Ltd スルホンアミド誘導体
US6355443B1 (en) * 1999-03-17 2002-03-12 Mark Norman Bobrow 4-(4-hydroxystyryl) pyridine-containing substrates for an analyte dependent enzyme activation system
WO2002057219A1 (fr) * 2001-01-18 2002-07-25 Welichem Biotech Inc. Nouveaux derives de 1,2-diphenylethene pour le traitement de maladies immunes
US20020177637A1 (en) * 2001-03-13 2002-11-28 The Ohio State University Polymers and oligomers, their synthesis, and electronic devices incorporating same
WO2004022665A1 (fr) * 2002-09-09 2004-03-18 National Institute Of Advanced Industrial Science And Technology Materiaux d'absorption biphotonique

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356221A (en) * 1971-08-04 1974-06-12 Pfizer 1- 3-hydroxystyryl- pyridinium salts and their derivatives as whipworm control agents
EP0334119A1 (fr) * 1988-03-21 1989-09-27 Boehringer Ingelheim Pharmaceuticals Inc. Composés pour l'inhibition de la biosynthèse de métabolites de l'acide arachidonique dérivés de la lipoxygénase
US5399575A (en) * 1990-12-01 1995-03-21 Boehringer Mannheim Gmbh Pyridine compounds which have useful pharmaceutical activity
EP0499415A1 (fr) * 1991-02-11 1992-08-19 Zeneca Limited Dérivés de pyridine et quinoléine, procédés pour leur fabrication et leur utilisation comme antagonistes de l'angiotensine II
PL172112B1 (pl) * 1993-08-09 1997-08-29 Univ Adama Mickiewicza Bromki (E)-N-dodecylo-/lub bromodecylo-/2-/3- lub 4-/hydroksy-a-stilbazoliowe i sposób otrzymywania nowych bromków (E)-N-dodecylo-/lub bromodecylo-/2-/3- lub 4-/hydroksy-a-stilbazoliowych
EP0754682A1 (fr) * 1994-04-06 1997-01-22 Nippon Shinyaku Company, Limited Derive d'aminostilbazole et medicament
US6355443B1 (en) * 1999-03-17 2002-03-12 Mark Norman Bobrow 4-(4-hydroxystyryl) pyridine-containing substrates for an analyte dependent enzyme activation system
JP2001261649A (ja) * 2000-03-15 2001-09-26 Sankyo Co Ltd スルホンアミド誘導体
WO2002057219A1 (fr) * 2001-01-18 2002-07-25 Welichem Biotech Inc. Nouveaux derives de 1,2-diphenylethene pour le traitement de maladies immunes
US20020177637A1 (en) * 2001-03-13 2002-11-28 The Ohio State University Polymers and oligomers, their synthesis, and electronic devices incorporating same
WO2004022665A1 (fr) * 2002-09-09 2004-03-18 National Institute Of Advanced Industrial Science And Technology Materiaux d'absorption biphotonique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HAROUTOUNIAN S A ET AL: "4'-Hydroxystyryldiazines: Synthesis and Fluorescence Properties", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 51, no. 6, February 1995 (1995-02-01), pages 1585 - 1598, XP004104849, ISSN: 0040-4020 *
HOWITZ K T ET AL: "SMALL MOLECULE ACTIVATORS OF SIRTUINS EXTEND SACCHAROMYCES CEREVISIAE LIFESPAN", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 425, 11 September 2003 (2003-09-11), pages 191 - 196, XP001188967, ISSN: 0028-0836 *
LAZER E S ET AL: "ANTIINFLAMMATORY 2,6-DI-TERT-BUTYL-4-(2-ARYLETHENYL)PHENOLS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 32, no. 1, 1989, pages 100 - 104, XP000973857, ISSN: 0022-2623 *
PAPA D; ET AL: "X-Ray Diagnostics. VI.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 73, 1951, pages 253 - 255, XP002388920 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 26 1 July 2002 (2002-07-01) *
PORCU M ET AL: "The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 26, no. 2, February 2005 (2005-02-01), pages 94 - 103, XP004727629, ISSN: 0165-6147 *
QUIDEAU S: "PLANT POLYPHENOLIC SMALL MOLECULES CAN INDUCE A CALORIE RESTRICTION-MIMETIC LIFE-SPAN EXTENSION BY ACTIVATING SIRTUINS: WILL POLYPHENOLS SOMEDAY BE USED AS CHEMOTHERAPEUTIC DRUGS IN WESTERN MEDICINE?", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, WILEY VCH, WEINHEIM, DE, vol. 5, no. 4, 2 April 2004 (2004-04-02), pages 427 - 430, XP009057585, ISSN: 1439-4227 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9162083B2 (en) 2007-07-31 2015-10-20 Elc Management Llc Linoleic and Linolenic acid esters of resveratrol and cosmetic compositions
US9220669B2 (en) 2007-09-08 2015-12-29 Elc Management Llc Resveratrol ferulate compounds, compositions containing the compounds, and methods of using the same

Also Published As

Publication number Publication date
WO2006078941A2 (fr) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2006078941A3 (fr) Nouveaux composes d'activation de la sirtuine et procedes d'utilisation associes
WO2006105440A3 (fr) Nicotinamide riboside et analogues
WO2006094210A3 (fr) Modulateurs de sirtuine de tetrahydroquinoxalinone
WO2006094209A3 (fr) Modulateurs de sirtuine a amide n-benzimidazolylalkyle substitue
WO2007019344A8 (fr) Dérivés d'imidazo [2,1-b] thiayole en tant que modulateurs de sirtuine
WO2008156869A3 (fr) Composés modulant les sirtuines
MY149316A (en) Sirtuin modulating imidazohiazole compounds
WO2006094246A3 (fr) Modulateurs de sirtuine a base de n-arylmethyl benzamide
WO2010037127A8 (fr) Analogues de chroménone en tant que modulateurs de sirtuine
WO2009134973A8 (fr) Quinoléines et analogues apparentés en tant que modulateurs de sirtuine
WO2009061453A8 (fr) Thiazolopyridines solubilisées
MY160006A (en) Thiazolopyridine sirtuin modulating compounds
IN2012DN03799A (fr)
WO2008100376A3 (fr) Variants de troncature de sirt1 et procédés d'utilisation de ceux-ci
MX2010004965A (es) Derivados de amida como moduladores de la sirtuina.
WO2007102861A3 (fr) Modulateurs de kinases de type cdc2 (clks) et leurs procédés d'utilisation
MX2011006084A (es) Isoindolinona y analogos relacionados como moduladores de sirtuina.
MX2010012961A (es) Imidazopiridina y analogos relacionados como moduladores de sirtuina.
MX2011006475A (es) Ftalazinona y analogos relacionados como moduladores de sirtuina.
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
WO2009085226A3 (fr) Inhibiteurs des kinases de type cdc2 (clk) et leurs procédés d'utilisation
WO2007127474A3 (fr) Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase
MX2011009213A (es) Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
WO2007104789A3 (fr) Dérivés d'amyline
WO2007130383A3 (fr) Compositions et traitements utilisant des pyridazines et des secrétases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06719063

Country of ref document: EP

Kind code of ref document: A2